KRAS and cancer: Therefore, KRAS A146-driven cancers may be sensitive to Son of Sevenless protein 1 (SOS1) inhibitors, combined with a MEK-inhibitor, or with SHP2, thus reinforcing the role of MEK inhibition in these tumours even in the current drug development scenario.